China coronary secondary prevention study (CCSPS): outcomes from analysis of coronary heart disease patients with diabetes / 中华心血管病杂志
Chinese Journal of Cardiology
; (12): 1067-1070, 2005.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-253011
Biblioteca responsável:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To elucidate whether lipid-lowering therapy with Xuezhikang can induce a decrease of cardiac events and an attenuation of total mortality in coronary heart disease (CHD) patients with diabetes.</p><p><b>METHODS</b>We designed a random, double-blinded, placebo controlled clinical trial in selected 591 patients. All patients were administrated with capsule Xuezhikang (0.6 g, Bid) or placebo in addition to conventional therapy. The mean follow-up period was four years. The primary end-points were nonfatal myocardial infarction and death from CHD.</p><p><b>RESULTS</b>(1) The incidence of CHD events and that of death from CHD were reduced by 50.8% (P = 0.0008) and by 44.1% (P = 0.0246) in treatment group, respectively; Also, the incidence of nonfatal myocardial infarction was reduced by 63.8% (P = 0.0151). (2) The incidence of stroke, tumor, and PCI/CABG were decreased by 20.2%. (3) The total mortality were lowered by 44.1% in treatment group (P = 0.0097).</p><p><b>CONCLUSION</b>Xuezhikang can effectively reduce the incidence of cardiac events and total mortality in CHD patients with diabetes.</p>
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Saúde e Bem-Estar
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Meta 3.4: Reduzir as mortes prematuras devido doenças não transmissíveis
/
Doença Cardiovascular
/
Diabetes Mellitus
/
Doenças do Sistema Endócrino
/
Doença Isquêmica do Coração
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Medicamentos de Ervas Chinesas
/
China
/
Método Duplo-Cego
/
Seguimentos
/
Doença das Coronárias
/
Usos Terapêuticos
/
Diabetes Mellitus
/
Tratamento Farmacológico
/
Prevenção Secundária
/
Hipolipemiantes
Tipo de estudo:
Ensaio clínico controlado
/
Estudo observacional
/
Estudo prognóstico
Limite:
Idoso
/
Feminino
/
Humanos
/
Masculino
País/Região como assunto:
Ásia
Idioma:
Chinês
Revista:
Chinese Journal of Cardiology
Ano de publicação:
2005
Tipo de documento:
Artigo